OBJECTIVES: (1) To determine the prevalence of metformin prescribing in type 2 diabetes with a contraindication and (2) to explore whether metformin use on top of contraindications modified the risks of lactic acidosis, hospitalization, and death in type 2 diabetes. SETTING: Ambulatory diabetic clinics of the secondary-level care General Hospital of Hatyai district, Songkhla province, South Thailand. METHOD: A cross-sectional study was carried out for the objective (1). A retrospective cohort study was applied to meet the objective (2). Out-patient medical case notes were reviewed for metformin use, number of hospitalizations, lactic acidosis cases, death cases, and the presence of contraindications, which were limited to: (1) chronic renal impairments, (2) chronic liver diseases, and (3) cardiac failure. Only documented diagnoses of the above conditions were counted. MAIN OUTCOME MEASURE: The prevalence of metformin use in type 2 diabetes with a contraindication; odds ratios (ORs) of the occurrences of lactic acidosis, hospitalization, and death in type 2 diabetes with a contraindication modified by metformin use. RESULTS: A total of 1,630 type 2 diabetic outpatients were identified; 19.3% (315/1,630) had at least one contraindication to metformin use, with chronic renal impairment being the most frequent risk (78%, 246/315). Of those with a contraindication, 84.4% (266/315) were metformin users. Compared to non-metformin users, there were no significant differences in the number of hospitalizations and deaths. No cases of lactic acidosis were evident. Metformin use in the presence of contraindications did not affect the risks of hospitalization (OR 0.73, 95% confidence interval [CI] 0.38-1.4, P = 0.34) or death (OR 0.58, 95% CI 0.11-3.15, P = 0.53). Other patient factors, such as the female gender or having diabetes-related complications, had significant influences on both outcomes. CONCLUSION: The prevalence of type 2 diabetes receiving metformin despite having a contraindication was over 80%. However, metformin use in such conditions did not appear to increase the risks of hospitalization and death. No lactic acidosis was reported. Other patient factors than metformin affect the risks of hospitalization and death.
OBJECTIVES: (1) To determine the prevalence of metformin prescribing in type 2 diabetes with a contraindication and (2) to explore whether metformin use on top of contraindications modified the risks of lactic acidosis, hospitalization, and death in type 2 diabetes. SETTING: Ambulatory diabetic clinics of the secondary-level care General Hospital of Hatyai district, Songkhla province, South Thailand. METHOD: A cross-sectional study was carried out for the objective (1). A retrospective cohort study was applied to meet the objective (2). Out-patient medical case notes were reviewed for metformin use, number of hospitalizations, lactic acidosis cases, death cases, and the presence of contraindications, which were limited to: (1) chronic renal impairments, (2) chronic liver diseases, and (3) cardiac failure. Only documented diagnoses of the above conditions were counted. MAIN OUTCOME MEASURE: The prevalence of metformin use in type 2 diabetes with a contraindication; odds ratios (ORs) of the occurrences of lactic acidosis, hospitalization, and death in type 2 diabetes with a contraindication modified by metformin use. RESULTS: A total of 1,630 type 2 diabetic outpatients were identified; 19.3% (315/1,630) had at least one contraindication to metformin use, with chronic renal impairment being the most frequent risk (78%, 246/315). Of those with a contraindication, 84.4% (266/315) were metformin users. Compared to non-metformin users, there were no significant differences in the number of hospitalizations and deaths. No cases of lactic acidosis were evident. Metformin use in the presence of contraindications did not affect the risks of hospitalization (OR 0.73, 95% confidence interval [CI] 0.38-1.4, P = 0.34) or death (OR 0.58, 95% CI 0.11-3.15, P = 0.53). Other patient factors, such as the female gender or having diabetes-related complications, had significant influences on both outcomes. CONCLUSION: The prevalence of type 2 diabetes receiving metformin despite having a contraindication was over 80%. However, metformin use in such conditions did not appear to increase the risks of hospitalization and death. No lactic acidosis was reported. Other patient factors than metformin affect the risks of hospitalization and death.
Authors: Dean T Eurich; Sumit R Majumdar; Finlay A McAlister; Ross T Tsuyuki; Jeffrey A Johnson Journal: Diabetes Care Date: 2005-10 Impact factor: 19.112
Authors: Savas Sipahi; Yalcin Solak; Seyyid Bilal Acikgoz; Ahmed Bilal Genc; Mehmet Yildirim; Ulku Yilmaz; Ahmet Nalbant; Ali Tamer Journal: Int Urol Nephrol Date: 2016-04-21 Impact factor: 2.370
Authors: Benjamin Lazarus; Aozhou Wu; Jung-Im Shin; Yingying Sang; G Caleb Alexander; Alex Secora; Lesley A Inker; Josef Coresh; Alex R Chang; Morgan E Grams Journal: JAMA Intern Med Date: 2018-07-01 Impact factor: 21.873
Authors: Sara Modig; Christina Lannering; Carl Johan Ostgren; Sigvard Mölstad; Patrik Midlöv Journal: BMC Geriatr Date: 2011-01-11 Impact factor: 3.921
Authors: Kamlesh Khunti; Thomas R Godec; Jesús Medina; Laura Garcia-Alvarez; Josh Hiller; Marilia B Gomes; Javier Cid-Ruzafa; Bernard Charbonnel; Peter Fenici; Niklas Hammar; Kiyoshi Hashigami; Mikhail Kosiborod; Antonio Nicolucci; Marina V Shestakova; Linong Ji; Stuart Pocock Journal: Diabetes Obes Metab Date: 2017-09-28 Impact factor: 6.577
Authors: K M Dungan; R Weitgasser; F Perez Manghi; E Pintilei; J L Fahrbach; H H Jiang; J Shell; K E Robertson Journal: Diabetes Obes Metab Date: 2016-02-19 Impact factor: 6.577